Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed adult T-cell leukemia/lymphoma (ATL) or cutaneous T-cell lymphoma (CTCL).
• •Reactivity of at least 10% of peripheral blood, lymph node, or dermal malignant cells with anti-Tac as determined by immunofluorescent staining or soluble IL-2 receptor level greater than 1,500 U required.
• •All stages of Tac-expressing T-cell leukemia and lymphoma eligible except Stage I CTCL.
• •All forms of ATL eligible, including the "smoldering" type as well as aggressive disease.
• •No symptomatic CNS disease other than tropical spastic paraparesis.
• •Asymptomatic CNS disease with demonstrable malignant cells in the CSF allowed (such patients receive CNS therapy, e.g., intrathecal methotrexate and/or CNS irradiation, as appropriate).
• •PRIOR/CONCURRENT THERAPY:
• •Biologic Therapy: Not specified.
• •Chemotherapy:
• •CTCL must have failed initial chemotherapy.
• •ATL may or may not have had prior chemotherapy.
• •At least 4 weeks since prior cytotoxic chemotherapy.
• •Endocrine Therapy: Not specified.
• •Radiotherapy: At least 4 weeks since prior radiotherapy.
• •Surgery: Not specified.
• •PATIENT CHARACTERISTICS:
• •Age: 18 and over.
• •Performance status: Not specified.
• •Life expectancy: Greater than 1 month.
• •Hematopoietic: WBC at least 3,000, Platelets at least 75,000.
• •Hepatic: Not specified.
• •Renal: Not specified.
• •Other:
• •No pregnant women.
• •Negative pregnancy test required of fertile women.